Skip to content

R&D at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.65B+17.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$46.74M+30.2%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$81.15M+11.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$104.52M+5.8%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$57.09M+21.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$126.64M+13.6%

Segments

By product

See full
Internal Research And Development$11.31M+67.6%
Bitopertin$9.34M+10.7%
DISC Three Four Zero Five$9.19M+451%
DISC Zero Nine Seven Four$8.11M+32.5%
Other Research$2.17M+18.2%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's R&D?
Disc Medicine (IRON) reported R&D of $45.9M in Q1 2026.
How has Disc Medicine's R&D changed year-over-year?
Disc Medicine's R&D increased by 65.3% year-over-year, from $27.76M to $45.9M.
What is the long-term trend for Disc Medicine's R&D?
Over 3 years (2022 to 2025), Disc Medicine's R&D has grown at a 72.2% compound annual growth rate (CAGR), from $33.44M to $170.64M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.